CD274 and hepatocellular carcinoma: The combination therapy of PD-L1 inhibitors with antiangiogenic agents, specifically the atezolizumab plus bevacizumab regimen, has been recommended by major clinical guidelines as first-line treatment for advanced HCC patients (3).